

ASX ANNOUNCEMENT

CELLMID GRANTED UK PATENT FOR USE OF MIDKINE FOR HAIR GROWTH

- Patent for use of midkine to prevent and treat hair loss and to promote and enhance hair growth issued
- Comprehensive protection over midkine and related protein pleiotropin with long patent life (to 2031)
- Patent boosts Cellmid hair growth asset portfolio

SYDNEY, 16 July 2014: Cellmid Limited (ASX: CDY) has received official Notification of Grant from the UK Intellectual Property Office (UKIPO) for Cellmid's patent application GB1216817.5 entitled *Method of treatment or prevention of hair loss or for the enhancement of hair growth*.

This patent protects the use of midkine and the closely related protein pleiotrophin for use as hair loss and/or hair growth treatments. The granted claims cover topical formulations of all kinds, including shampoos, conditioners, creams and lotions with protection until 2031.

This patent is the first granted member of the extensive midkine patent family for hair growth. Other patents are filed or are under examination in the US, Europe, China, Hong Kong, Japan, Korea and Australia.

This patent family adds to the already considerable intellectual property assets of Cellmid's wholly owned anti-aging hair growth subsidiary, Advangen, which include patent protection and extensive know-how around its FGF5 inhibiting technologies, cell based assays, formulations and brands.

Advangen's products are on sale in Australia, China and Japan; in the future the company aims to bolster its distribution in these countries and expand to the USA, Europe and South America. Advangen's business is underpinned by an innovative and scientifically validated product pipeline including novel FGF5 inhibitors as well as midkine-based products.

The anti-aging hair care area is one of the fastest growing segments of the estimated \$90 billion annual hair care market. There is a dearth of biologically active products which improve hair growth, hair quality and reduce hair loss. Cellmid, through its wholly owned subsidiary Advangen, is well positioned to take a leading role in this market with its range of biologically active high tech products and technologies.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in immunoncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen International and FGF-5 inhibitor hair growth products

In 2010 Cellmid set up a dedicated subsidiary, Advangen International Pty Ltd, for the development of midkine for hair growth. While developing this program, the Company launched a range of FGF-5 inhibitor hair growth products on the market in 2012 under license and acquired the owner of the technology, Advangen Inc. (Japan) in May 2013. Since then, Cellmid has been actively building its distribution in Australia, China, Japan and other major markets. In addition to its FGF5 inhibitors Cellmid is also developing a strong product pipeline using midkine for hair growth.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.